• While most Candida albicans remain sensitive to fluconazole and amphotericin B, fluconazole-resistant C. albicans and non-albicans Candida spp. that may be less susceptible to azoles are being recognized with increased frequency.
• C. krusei is resistant and C. glabrata demonstrates decreased susceptibility to fluconazole. C. lusitaniae is resistant to amphotericin B and flucytosine, but remains susceptible to azoles.
• Aspergillus spp. do not respond to fluconazole, but amphotericin B and itraconazole may have efficacy, especially if predisposing immune defects can be corrected.
• Itraconazole now plays an important role in management of blastomycosis and histoplasmosis, although amphotericin B is still used for severe disease.
• Treatment of zygomycosis, hyalohyphomycosis, and phaeohyphomycosis is challenging and involves aggressive antifungal therapy, adjunctive surgery if possible, and correction of underlying immune defects.
• Guidelines for management of dermatomycoses have been published by the American Academy of Dermatology.
• Susceptibility testing for Candida species and Cryptococcus neoformans has now been standardized but is still used predominantly for exceptional patient care decisions and research purposes.
• New antifungal drugs are urgently needed and several are currently being studied.
• Practice guidelines are available from the IOSA to guide treatment of many fungal diseases (31).
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.